Mayne Pharma Group Ltd
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals.
The business
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others. Its subsidiaries include Mayne Pharma International Pty Ltd, Mayne Holdings US Inc, Mayne Pharma LLC, and others.
Small Caps Research
No research on Mayne Pharma Group Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise MYX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Market wrap: Lack of tech saves Australian market after Wall Street rout
Australia’s market fell just 0.5% after Wall Street’s AI rout wiped US$3.3 trillion in value, as banks and defensive stocks cushioned mining losses.
Mayne Pharma Sells International Operations for $55.5m to Focus on US Business
Mayne Pharma sells international operations for $55.5m, sharpening its focus on US Women’s Health, Dermatology and DistributeRx growth.
Mayne Pharma board backs $672 million takeover bid from Cosette Pharma
Mayne Pharma (ASX: MYX) has received a takeover offer at a price of $7.40 per share from US-based pharmaceutical company Cosette Pharma, valuing the company at $672 million. Cosette has a portfolio of products in women’s health and dermatology and a long history of manufacturing complex dosage forms including topical creams, ointments, oral liquids/solutions and […]
Mayne Pharma forecasts up to $215m revenue for 1H25 as growth momentum continues
Mayne Pharma (ASX: MYX) has reported a forecast revenue of between $210 million and $215m for the first half of the 2025 financial year, reflecting growth of approximately 14% on the previous corresponding period (pcp). The company is also expecting to report underlying EBITDA of between $30m and $32m, representing an increase of almost 300% […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.